Featured Research

from universities, journals, and other organizations

Revolutionary new way of reversing certain cancers

Date:
September 29, 2010
Source:
Garvan Institute of Medical Research
Summary:
Australian and American scientists have found a way of shrinking tumors in certain cancers -- a finding that provides hope for new treatments. The cancers in question are those caused by a new class of genes known as "microRNAs," produced by parts of the genome that, until recently, were dismissed as "junk DNA." While much is still unknown about microRNAs, it is clear that they can interfere with how our genes are "read."

Australian and American scientists have found a way of shrinking tumours in certain cancers -- a finding that provides hope for new treatments.

Related Articles


The cancers in question are those caused by a new class of genes known as 'microRNAs', produced by parts of the genome that, until recently, were dismissed as 'junk DNA'. While much is still unknown about microRNAs, it is clear that they can interfere with how our genes are 'read'.

The current finding identifies one particular microRNA (microRNA 380) that appears to disable the king of tumour suppressors, the p53 gene. So important is p53, that it is known as the 'guardian of the genome'. In order for a cell to become cancerous, p53 must either be mutated or otherwise disabled.

Dr Alex Swarbrick, from Sydney's Garvan Institute of Medical Research, Dr Susan Woods from Brisbane's Queensland Institute of Medical Research and Dr Andrei Goga from The University of California San Francisco chose to study neuroblastoma, a childhood cancer of the nervous system in which 99% of patients do not have mutations of the p53 gene.

The researchers found instead that neuroblastomas disable p53 by over-producing microRNA 380. When they blocked the microRNA, p53 production resumed, cancer cells died and tumours became much smaller. Their results are reported in the journal Nature Medicine.

"The revolutionary thing about this finding is that it's the first time anyone has blocked the growth of a primary tumour by the simple delivery of a microRNA inhibitor," said Swarbrick.

"By that, I mean we delivered the microRNA inhibitor in a way we might give it to a person -- as a twice-weekly injection -- not using some genetic trick. It's the closest thing to a clinical result that's yet been published."

"That, of course, makes this microRNA a potential therapeutic target for all cancers that depend on it."

"The other good news is that you don't find this microRNA in normal adult cells. It's very active while we are developing embryos, when cells need to divide very quickly, but after that it appears to get switched off. So by blocking it, you're effectively returning cells to normal."

"We still don't know why it gets switched on again in certain cancers. Apart from neuroblastomas, we often see it in brain tumours and in melanomas that don't have mutations in p53."

So how exactly does it work?

When a gene is transcribed or "read," in this case p53, a copy of the gene is made in RNA. In a normal cell, that p53 RNA carries the instructions to make p53 proteins, which in turn carry out the tumour suppressor function in cells.

"MicroRNAs act to control the production of proteins -- the molecules that do the work in cells," explained Swarbrick.

"In the cancers we are discussing, our microRNA binds with p53 RNA, preventing it from making proteins. That effectively reduces the number of p53 proteins in a cell and allows the tumour to grow."

"Understanding that certain cancers appear to be regulated like this gives us a new avenue to explore in their treatment."

While this finding is at an early research stage, it holds much promise for the future treatment of early childhood neuroblastomas and other microRNA- induced cancers.


Story Source:

The above story is based on materials provided by Garvan Institute of Medical Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexander Swarbrick, Susan L Woods, Alexander Shaw, Asha Balakrishnan, Yuwei Phua, Akira Nguyen, Yvan Chanthery, Lionel Lim, Lesley J Ashton, Robert L Judson, Noelle Huskey, Robert Blelloch, Michelle Haber, Murray D Norris, Peter Lengyel, Christopher S Hackett, Thomas Preiss, Albert Chetcuti, Christopher S Sullivan, Eric G Marcusson, William Weiss, Noelle L'Etoile, Andrei Goga. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nature Medicine, 2010; DOI: 10.1038/nm.2227

Cite This Page:

Garvan Institute of Medical Research. "Revolutionary new way of reversing certain cancers." ScienceDaily. ScienceDaily, 29 September 2010. <www.sciencedaily.com/releases/2010/09/100928092843.htm>.
Garvan Institute of Medical Research. (2010, September 29). Revolutionary new way of reversing certain cancers. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2010/09/100928092843.htm
Garvan Institute of Medical Research. "Revolutionary new way of reversing certain cancers." ScienceDaily. www.sciencedaily.com/releases/2010/09/100928092843.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins